[HTML][HTML] Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain …
E Raymond, AA Brandes, C Dittrich… - Journal of Clinical …, 2008 - ncbi.nlm.nih.gov
Journal of Clinical Oncology, 2008•ncbi.nlm.nih.gov
Results A total of 112 patients (51 patients with GBM, 25 patients with A, and 36 patients with
OD) were enrolled. Imatinib was in general well tolerated. The median number of cycles was
2.0 (range, 1 to 43 cycles). Five patients had an objective partial response, including three
patients with GBM; all had 6 months of PFS. The 6-month PFS rate was 16%(95% CI, 8.0%
to 34.0%) in GBM, 4.0%(95% CI, 0.3% to 15.0%) in OD, and 9%(95% CI, 2.0% to 25.0%) in
A. The exposure to imatinib was significantly lower in patients using enzyme-inducing …
OD) were enrolled. Imatinib was in general well tolerated. The median number of cycles was
2.0 (range, 1 to 43 cycles). Five patients had an objective partial response, including three
patients with GBM; all had 6 months of PFS. The 6-month PFS rate was 16%(95% CI, 8.0%
to 34.0%) in GBM, 4.0%(95% CI, 0.3% to 15.0%) in OD, and 9%(95% CI, 2.0% to 25.0%) in
A. The exposure to imatinib was significantly lower in patients using enzyme-inducing …
Results
A total of 112 patients (51 patients with GBM, 25 patients with A, and 36 patients with OD) were enrolled. Imatinib was in general well tolerated. The median number of cycles was 2.0 (range, 1 to 43 cycles). Five patients had an objective partial response, including three patients with GBM; all had 6 months of PFS. The 6-month PFS rate was 16%(95% CI, 8.0% to 34.0%) in GBM, 4.0%(95% CI, 0.3% to 15.0%) in OD, and 9%(95% CI, 2.0% to 25.0%) in A. The exposure to imatinib was significantly lower in patients using enzyme-inducing antiepileptic drugs. The presence of ABCG2 point mutations were not correlated with pharmacokinetic findings. No somatic activating mutations of KIT or platelet-derived growth factor receptor–A or–B were found.
Conclusion
In the dose range of 600 to 1,000 mg/d, single-agent imatinib is well tolerated but has limited antitumor activity in patients with recurrent gliomas.
ncbi.nlm.nih.gov